Business / Corporate Sep 6, 2021
Daiichi Sankyo positions its COVID-19 vaccine as a booster in Japan
by Lisa Du and Grace Huang
Daiichi Sankyo is aiming for full regulatory approval by the second half of next year.
National / Science & Health Mar 23, 2021
Japanese firms launch domestic clinical trials for COVID-19 vaccines
by Osamu Tsukimori
Even as Daiichi Sankyo and KM Biologics begin work to prove their shots' efficacy and safety, the public is unlikely to have access to them until fiscal 2022 at the earliest.
National Mar 12, 2021
Daiichi Sankyo Co. on Thursday began the vial filling and packaging of the vaccine using undiluted solutions provided by AstraZeneca.
National Dec 4, 2020
Japan-made coronavirus vaccines may not be available until 2022
Only one company in Japan is conducting a trial of a vaccine.
National / Science & Health Aug 31, 2020
Daiichi Sankyo's COVID-19 vaccine candidate selected by Japanese drug discovery body
Daiichi Sankyo Co. said on Monday that its mRNA-based COVID-19 vaccine candidate was selected for inclusion in a drug discovery program by the Japan Agency for Medical Research and Development. The vaccine, known as DS-5670, was picked for the second round of AMED's program dedicated ...
National / Science & Health Jun 12, 2020
Daiichi Sankyo sees clinical test for genetic COVID-19 vaccine in March
The vaccine contains messenger RNA that causes cells to produce proteins that could trigger the body to produce effective antibodies.
National / Science & Health Jun 16, 2019
Drug devised to replace chemotherapy may reshape cancer care
by Kanoko Matsuyama
A class of drugs is emerging that can attack cancer cells in the body without damaging surrounding healthy ones. They have the potential to replace chemotherapy and its disruptive side effects, reshaping the future of cancer care. The complex biological medicines, called antibody drug conjugates ...
Business / Corporate Mar 29, 2019
AstraZeneca bets $6.9 billion that Daiichi Sankyo therapy will transform cancer treatment
Britain’s AstraZeneca’s biggest deal in recent memory give it access to the Japanese drugmaker’s promising but difficult to pronounce cancer treatment: trastuzumab deruxtecan.
Business / Corporate Sep 29, 2017
Opioids demand rises in Japan as seniors use drugs to ease pain and improve quality of life
by Kanoko Matsuyama
Selling painkillers in Japan used to be like pulling teeth. That was until baby boomers discovered how analgesics could take the sting from arthritis, diabetic nerve damage and the ravages of cancer. Now demand is taking off and drugmakers are introducing new products to a ...
Business / Corporate Aug 2, 2017
Daiichi Sankyo Inc. has settled thousands of lawsuits alleging its blood-pressure drugs caused intestinal damage, bringing to $339 million the amount the drugmaker has paid over the medicines. Daiichi officials agreed Monday to pay $300 million to resolve patient suits over its blood-pressure treatments Benicar, ...
Business / Corporate May 6, 2016
Daiichi Sankyo awarded damages over cover-up at Indian ex-subsidiary
Daiichi Sankyo Co. said Friday that an international arbitration court has ordered former shareholders of an Indian firm it acquired in 2008 to pay the drugmaker around ¥56.2 billion ($524 million) for concealing critical information. Daiichi Sankyo sold its stake in Ranbaxy Laboratories Ltd. to ...